JNJ-26481585 (Quisinostat) is an HDAC inhibitor. It has a second generation histone deacetylase inhibitor with antineoplastic activities. It inhibits well for HDAC1 (IC50 = 0.11 nM), HDAC2 (IC50 = 0.33 nM), HDAC4 (IC50 = 0.64 nM), HDAC10 (IC50 = 0.46 nM), HDAC11 (IC50 = 0.37 nM).
Soluble in DMSO (79 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), ethanol (<1 mg/ml at 25 °C), and 15% Captisol (30 mg/ml at 25 °C).
Adobe Acrobat Reader is required to reliably view, print and comment on PDF documents
bvseo_sdk, java_sdk, bvseo-3.2.0
CLOUD, getContent, 106ms
bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of
SchremlSchreml, J. et al. (PubMed 23073311) reported that severe spinal muscular atrophy mice show organ impairment that cannot be rescued by therapy with the HDAC inhibitor JNJ-26481585. -SCBT Publication Review
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn